- Home
- APCX vs KZIA Comparison
APCX vs KZIA Comparison
Compare APCX & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APCX
- KZIA
- Stock Information
- Founded
- APCX 2006
- KZIA 1994
- Country
- APCX United States
- KZIA Australia
- Employees
- APCX N/A
- KZIA N/A
- Industry
- APCX Finance: Consumer Services
- KZIA Biotechnology: Pharmaceutical Preparations
- Sector
- APCX Finance
- KZIA Health Care
- Exchange
- APCX Nasdaq
- KZIA Nasdaq
- Market Cap
- APCX 15.8M
- KZIA 12.6M
- IPO Year
- APCX N/A
- KZIA 1999
- Fundamental
- Price
- APCX $0.52
- KZIA $0.43
- Analyst Decision
- APCX
- KZIA Strong Buy
- Analyst Count
- APCX 0
- KZIA 1
- Target Price
- APCX N/A
- KZIA $2.00
- AVG Volume (30 Days)
- APCX 278.2K
- KZIA 1.7M
- Earning Date
- APCX 11-12-2024
- KZIA 10-08-2024
- Dividend Yield
- APCX N/A
- KZIA N/A
- EPS Growth
- APCX N/A
- KZIA N/A
- EPS
- APCX N/A
- KZIA N/A
- Revenue
- APCX $462,000.00
- KZIA $382.00
- Revenue This Year
- APCX $1,315.48
- KZIA $4,053,954.00
- Revenue Next Year
- APCX N/A
- KZIA N/A
- P/E Ratio
- APCX N/A
- KZIA N/A
- Revenue Growth
- APCX 3.59
- KZIA N/A
- 52 Week Low
- APCX $0.44
- KZIA $0.19
- 52 Week High
- APCX $3.36
- KZIA $1.58
- Technical
- Relative Strength Index (RSI)
- APCX 25.30
- KZIA 60.74
- Support Level
- APCX $0.54
- KZIA $0.31
- Resistance Level
- APCX $0.62
- KZIA $0.51
- Average True Range (ATR)
- APCX 0.08
- KZIA 0.03
- MACD
- APCX -0.02
- KZIA 0.01
- Stochastic Oscillator
- APCX 16.06
- KZIA 59.30
About APCX AppTech Payments Corp.
AppTech Payments Corp is a FinTech company utilizing various payment processing and digital banking technologies to complement core merchant services capabilities. The company's patented and proprietary software will provide progressive and adaptable products that are available through a suite of synergistic offerings directly to merchants, banking institutions, and business enterprises. It is developing a secure digital payments and banking platform that powers commerce experiences for clients and customers. Based upon industry standards for payment and banking protocols, the company will offer standalone products and fully integrated solutions that deliver unparalleled payments, banking, and financial services experiences.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing innovative anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors.